Introduction
MEHOW INNOVATIVE LTD. (Chinese: 深圳市美好创亿医疗科技股份有限公司, stock code 301363, commonly known as 美好医疗) is a Shenzhen-based medical-device CDMO/contract manufacturing company that designs, develops, manufactures, and sells precision components and finished products for healthcare customers in China and international markets. Founded in 2010 and headquartered in Shenzhen, Guangdong, the company has positioned itself around integrated, full-process medical device services, spanning product development, tooling, molding, secondary processing, assembly, and regulated mass production.
The company’s industrial profile is closely tied to plastics-intensive medical manufacturing, especially precision molding, liquid silicone rubber (LSR) injection molding, multi-component molding, and automated assembly for high-specification device components. Its reported product scope extends across home ventilator components, cochlear implant components, microfluidic and laboratory consumables, cardiovascular and surgical solutions, respiratory testing products, and selected consumer and personal-care applications that leverage medical-grade manufacturing capabilities.
Mehow’s market relevance lies in its role as an upstream manufacturing and engineering partner for medical device brands that outsource development and production under contract manufacturing and marketing authorization holder arrangements. In that model, the company participates not only in plastics processing but also in regulatory, quality, and industrialization workflows that are central to the global medical device supply chain.
History and Development
Mehow Innovative was established on 15 July 2010 in Shenzhen, originally as 深圳市美好创亿医疗科技有限公司, before later transforming into a joint-stock company. The company subsequently completed its shareholding reform and, according to its IPO materials, became a joint-stock company in November 2019.
A major development milestone came with its listing on the Shenzhen Stock Exchange in the growth market, after which the company operated as a publicly listed medical technology manufacturer under the ticker 301363. This transition formalized its status as a capital-market participant and increased disclosure around its operations, product categories, and regulatory framework.
By 2023 and 2024, the company described its core business as providing global medical-device customers with a one-stop service from design and development to batch delivery, indicating a shift from component manufacturing alone toward broader CDMO-oriented integration. In later disclosures, the company also indicated that its business coverage had expanded across multiple medical-device sub-segments, including diagnostics, surgery, orthopedics, robotics-related areas, and other diversified track-based applications.
Business Operations and Segments
Mehow’s operations are centered on medical device precision components and products, with a business model that combines engineering development, tooling, molding, automated production, and final assembly. The company presents itself as a manufacturing services provider for global medical-device customers, rather than a pure-brand device seller.
Its activity can be grouped into several operational areas:
- Design and development of device components and assemblies.
- Tooling and precision molding, including plastic and silicone processing.
- Secondary processing and finishing, supporting sterilizable and regulated medical applications.
- Automated assembly and full-product delivery, particularly for high-volume outsourcing programs.
- Quality and compliance management, aligned with medical-device regulatory requirements across major markets.
This structure makes the company relevant to the medical plastics value chain because it transforms engineering polymers and elastomers into highly controlled, application-specific parts used in clinical and diagnostic systems.
Products and Technologies
The company’s reported portfolio includes a broad range of medical-device components and related products. Key categories include:
- Home ventilator components and related respiratory-device parts.
- Cochlear implant components.
- Microfluidic solutions and laboratory consumables, including cuvettes, PCR tubes, 96-well plates, freezing tubes, culture dishes, bottles, suction heads, and vacutainers.
- Cardiovascular products, including electrophysiology and ablation catheter components, high-density mapping catheter products, and intracardiac echocardiography solutions.
- Surgical solutions, such as ultrasonic scalpels, staplers, ligating clips, sterile-grade and implant-grade injection components, and micro precision equipment components.
- Ophthalmology and ENT consumables, including phacoemulsification disposables, intraocular lens delivery systems, hearing-aid and cochlear-implant related components.
- Respiratory testing equipment and consumables, including ventilator consumables, pulmonary function testers, and disposable filters.
- Other healthcare-related products, including enteral nutrition infusion sets, nasogastric tubes, stoma tubes, neuromodulation devices, and women’s health products.
From a plastics-manufacturing perspective, several technologies are especially significant. Mehow identifies precision molds, plastic and liquid silicone molding, LSR/plastic multi-component molding, micro-assembly, sensor integration, and automation equipment as core capabilities. These capabilities are central to medical polymer processing because they support tight dimensional tolerances, cleanliness, traceability, and repeatable production for regulated end uses.
Applications and End Markets
Mehow serves multiple medical and adjacent end markets, with a strong concentration in device categories that require engineered polymer components and clean manufacturing environments.
Its principal end markets include:
- Respiratory care, including ventilator-related components and testing consumables.
- Neurostimulation and implant-adjacent applications, including cochlear implant-related components.
- Cardiovascular intervention, where catheters and mapping-related components depend on precise polymer-based assemblies.
- Surgical devices, including disposable and semi-disposable components with demanding sterilization and biocompatibility requirements.
- Diagnostics and laboratory consumables, which rely heavily on injection-molded plastics and controlled fluid handling design.
- Ophthalmology and ENT, where miniature and high-clarity polymer parts are important to device function.
The company also references some non-medical or semi-adjacent categories, including baby and maternity products, consumer electronics, drinking water bottles, and personal care items, indicating that its manufacturing platform can extend beyond healthcare where plastics engineering, molding, and assembly overlap. These additional categories are not the core of the company’s identity, but they illustrate the flexibility of its industrial base.
Global Presence and Market Position
Mehow is headquartered in Shenzhen and operates from facilities in the city’s Longgang district, with corporate and production addresses disclosed in regulatory filings. The company describes its customer base as global and states that it provides services for medical-device enterprises in China and internationally.
The company’s market position is best understood as that of a specialized medical manufacturing platform rather than a mass-market plastics converter. Its reported scale includes more than 2,000 employees in multiple third-party company profiles, suggesting a mid-sized industrial base within the medical-device supply chain. Public materials also indicate a diversified portfolio across several medical sub-segments, supporting a model that balances customer concentration risk with multi-product engineering capability.
Research and Development
Research and development is a central part of Mehow’s business model. The company emphasizes design and development, tooling, process engineering, and automated manufacturing as part of its end-to-end service offering.
Its R&D-related strengths are closely tied to process innovation in medical plastics manufacturing, especially:
- Precision mold development
- LSR and plastic multi-material molding
- Micro-assembly
- Automation for repeatable high-volume production
- Sensor integration for advanced device subassemblies
These capabilities are strategically important because medical-device outsourcing increasingly demands not only low-cost manufacturing but also validated processes, rapid design iteration, and compatibility with regulatory pathways in major markets.
Sustainability and Environmental Initiatives
Mehow’s public materials indicate that it maintains formal management systems including ISO 14001 environmental management certification and OHSAS/OHSMS 18001 occupational health and safety systems, alongside ISO 9001, IATF 16949, and GMP-related references. The company also states that its quality management framework is aligned with ISO 13485 and with regulatory expectations associated with the EU CE, U.S. FDA, and China’s NMPA regimes.
For a medical plastics manufacturer, these systems are significant because environmental and quality control processes affect not only compliance but also the contamination control, waste handling, and traceability required for regulated device production. In the broader industry context, such systems are increasingly relevant as medical-device customers seek suppliers capable of demonstrating controlled manufacturing and responsible operations.
Financial Performance and Economic Impact
The company reported RMB 1.415 billion in revenue for 2022, representing a year-on-year increase of 24.43% according to its board report. Later annual and interim filings show that the company continued operating as a publicly listed enterprise with disclosed quarterly and half-year reporting obligations on the Shenzhen exchange.
Economically, Mehow contributes to the regional industrial ecosystem of Shenzhen and the Pearl River Delta by combining medical-device engineering with plastics processing, precision tooling, and automated assembly. Its business model supports downstream medical brands that outsource development and production, while also anchoring local employment, supplier networks, and industrial service demand.
Quality Management and Certifications
Quality management is a defining feature of Mehow’s manufacturing identity. Public company and manufacturing profiles state that the company operates under ISO 13485 medical-device quality management requirements and has established systems aligned with EU CE, U.S. FDA, and NMPA expectations.
Additional certifications and management systems reported in third-party industrial listings include:
- ISO 9001
- ISO 14001
- IATF 16949
- GMP
- OHSAS/OHSMS 18001
For a supplier serving medical customers, these certifications support process control, traceability, and compliance across design, molding, assembly, and final product delivery.
Innovations and Future Outlook
Mehow’s future prospects are linked to several structural trends in the medical-device industry: outsourcing of complex manufacturing, growth in diagnostics and home healthcare, demand for miniaturized components, and rising emphasis on validated polymer processing. Its combination of precision molding, automation, and multi-material assembly places it in a segment of the plastics industry where engineering capability is often as important as unit cost.
The company’s disclosed expansion across multiple therapeutic and device categories suggests an ongoing strategy of diversification within healthcare manufacturing, which may reduce dependence on any single product line while increasing technical complexity. As medical-device makers continue to separate design ownership from manufacturing execution, Mehow’s integrated CDMO model is positioned to remain relevant in supply chains that require both regulatory discipline and advanced plastics-processing expertise.
References
- •
CPS+ eMarketplace. (n.d.). MEHOW INNOVATIVE LTD.MEHOW INNOVATIVE LTD.. CPS+ eMarketplace. https://www.chinaplasonline.com/eMarketplace/ExhibitorInfo?CompId=1034709Link